Opinion
1don MSNOpinion
Hims insider makes first stock purchase since 2021 amid weight-loss drug pivot
Hims & Hers Health shares have slumped in 2026 as the telehealth provider moves away from selling compounded GLP-1 medications.
2d
HIMS Stock Eyes Breakout Week: Eight New Partners Fuel Push To Build An All-In-One Health Platform
CEO Andrew Dudum said Hims is building "an entire health ecosystem" rather than serving as a solution for a single health ...
Hims & Hers Health jumped about 5% on Wednesday after director David Wells disclosed a purchase of more than $1 million in company stock, ...
Stocktwits on MSN
HIMS stock heads for weekly loss — but ex-Netflix CFO is buying the dip despite BofA’s GLP-1 warning
Former Netflix CFO and Hims board member David Wells bought 48,400 shares worth about $1.17 million. ・Investor concerns intensified after Hims reported weak Q1 results that missed revenue and earnings ...
Hims & Hers Health added more than ~7% in the early morning hours on Wednesday after David Wells, a director of the ...
Hims & Hers Health (NYSE: HIMS) delivered another quarter of strong revenue growth. But that came with shrinking margins, rising costs, and a surprise net loss. Will AI create the world's first ...
Hims & Hers (HIMS) stock up 41% as Q1 revenue hits $608M and international sales surge 969% on ZAVA/Livewell deals.
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest ...
Hims & Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term profitability story.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results